文献速递乳腺癌

曲妥珠单抗联合卡培他滨联合或不联合帕妥珠单抗治疗曲妥珠单抗治疗期间或之后疾病进展的HER2阳性转移性乳腺癌患者的随机III期试验

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
PubMed 文献 · J Clin Oncol · 2017-04-24

本研究为随机III期试验,纳入曲妥珠单抗治疗期间或之后进展且接受过紫杉类治疗的HER2阳性转移性乳腺癌患者,随机接受曲妥珠单抗联合卡培他滨(A组)或帕妥珠单抗联合曲妥珠单抗及卡培他滨(B组)治疗。主要终点独立评审机构评估的无进展生存期(IRF PFS)在两组分别为9.0个月与11.1个月(HR 0.82,95%CI 0.65-1.02,P=0.0731),差异未达统计学显著。中期总生存期(OS)分别为28.1个月与36.1个月(HR 0.68,95%CI 0.51-0.90),但因分层检验未声称统计学显著。

要点

  • 在曲妥珠单抗治疗后进展的HER2阳性转移性乳腺癌中,加用帕妥珠单抗未显著改善IRF PFS。
  • B组中位OS较A组延长8个月(36.1个月 vs 28.1个月),但受分层检验限制不能声称统计学显著。
  • 两组常见不良事件不同:A组为手足综合征、恶心、中性粒细胞减少;B组为腹泻、皮疹、鼻咽炎。

关键数值与推荐

  • A组方案:曲妥珠单抗8 mg/kg→6 mg/kg 每3周一次,联合卡培他滨1,250 mg/m2 每日两次(服2周停1周,每3周重复)。
  • B组方案:帕妥珠单抗840 mg→420 mg 每3周一次,联合曲妥珠单抗(剂量与 schedule 同A组)及卡培他滨1,000 mg/m2( schedule 同A组)。
  • 主要终点IRF PFS:A组9.0个月 vs B组11.1个月(HR 0.82,95%CI 0.65-1.02,P=0.0731)。
  • 中期OS:A组28.1个月 vs B组36.1个月(HR 0.68,95%CI 0.51-0.90)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy and received a prior taxane. Patients and Methods Patients were randomly assigned to arm A: trastuzumab 8 mg/kg → 6 mg/kg once every 3 weeks plus capecitabine 1,250 mg/m2 twice a day (2 weeks on, 1 week off, every 3 weeks); or arm B: pertuzumab 840 mg → 420 mg once every 3 weeks plus trastuzumab at the same dose and schedule as arm A plus capecitabine 1,000 mg/m2 on the same schedule as arm A. The primary end point was independent review facility-assessed progression-free survival (IRF PFS). Secondary end points included overall survival (OS) and safety. Hierarchical testing procedures were used to control type I error for statistical testing of IRF PFS, OS, and objective response rate. Results Randomly assigned (intent-to-treat) populations were 224 and 228 patients in arms A and B, respectively. Median IRF PFS at 28.6 and 25.3 months' median follow-up was 9.0 v 11.1 months (hazard ratio, 0.82; 95% CI, 0.65 to 1.02; P = .0731) and interim OS was 28.1 v 36.1 months (hazard ratio, 0.68; 95% CI, 0.51 to 0.90). The most common adverse events (all grades; incidence of ≥ 10% in either arm and ≥ 5% difference between arms) were hand-foot syndrome, nausea, and neutropenia in arm A, and diarrhea, rash, and nasopharyngitis in arm B. Conclusion The addition of pertuzumab to trastuzumab and capecitabine did not significantly improve IRF PFS. An 8-month increase in median OS to 36.1 months with pertuzumab was observed. Statistical significance for OS cannot be claimed because of the hierarchical testing of OS after the primary PFS end point; however, the magnitude of OS difference is in keeping with prior experience of pertuzumab in metastatic breast cancer. No new safety signals were identified.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Urruticoechea A, Rizwanullah M, Im SA, et al. Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. J Clin Oncol. 2017. PMID: 28437161. doi:10.1200/JCO.2016.70.6267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。